When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ALBO - Albireo's odevixibat shows encouraging action in mid-stage study
Albireo Pharma Inc.
Albireo Pharma (NASDAQ:ALBO) announces positive data from a Phase 2 clinical trial evaluating lead candidate odevixibat (A4250) in patients with three rare liver/bile duct disorders: biliary atresia, Alagille syndrome and progressive familial intrahepatic cholestasis. The results were presented at the European Society for Paediatric Gastroenterology, Hepatology and Nutrition Annual Meeting in Glasgow, Scotland.
More news on: Albireo Pharma, Inc., Healthcare stocks news,